Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Primo N Lara

Showing results (141-150 of 274) with videos related to

Pageof 28
Sort By:
Scientific Reports|March 19, 2021
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancerMamta Parikh, Chengfei Liu, Chun-Yi Wu, et al.
Cancers|December 11, 2022
The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical CystectomyGiovanni E Cacciamani, Afsaneh Barzi, Michael B Eppler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 10, 2014
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trialsPrimo N Lara, James Moon, Mary W Redman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2016
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics AssayPrimo N Lara, James Moon, Paul J Hesketh, et al.
American Journal of Hematology|July 12, 2002
Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trialStephen E Wang, Primo N Lara, Angie Lee-Ow, et al.
Cancer|November 17, 2007
Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaignAri Umutyan, Christine Chiechi, Laurel A Beckett, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2011
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trialRandeep Sangha, Angela M Davies, Primo N Lara, et al.
Cancer Chemotherapy and Pharmacology|March 30, 2017
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancerHeather A Wakelee, Scott Gettinger, Jeffrey Engelman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2008
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I studyAngela M Davies, Christopher Ruel, Primo N Lara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on ErlotinibPrimo N Lara, Jeff Longmate, Philip C Mack, et al.
Pageof 28

Showing results (141-150 of 274) with videos related to

Sort By:
Pageof 28
Scientific Reports|March 19, 2021
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancerMamta Parikh, Chengfei Liu, Chun-Yi Wu, et al.
Cancers|December 11, 2022
The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical CystectomyGiovanni E Cacciamani, Afsaneh Barzi, Michael B Eppler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 10, 2014
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trialsPrimo N Lara, James Moon, Mary W Redman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2016
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics AssayPrimo N Lara, James Moon, Paul J Hesketh, et al.
American Journal of Hematology|July 12, 2002
Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trialStephen E Wang, Primo N Lara, Angie Lee-Ow, et al.
Cancer|November 17, 2007
Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaignAri Umutyan, Christine Chiechi, Laurel A Beckett, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2011
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trialRandeep Sangha, Angela M Davies, Primo N Lara, et al.
Cancer Chemotherapy and Pharmacology|March 30, 2017
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancerHeather A Wakelee, Scott Gettinger, Jeffrey Engelman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2008
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I studyAngela M Davies, Christopher Ruel, Primo N Lara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on ErlotinibPrimo N Lara, Jeff Longmate, Philip C Mack, et al.
Pageof 28